Oncolytics to present REO 033 trial-in-progress abstract at ESMO 2026 Congress
Oncolytics Biotech said it will present a trial-in-progress abstract and e-poster on its randomized REO 033 study of pelareorep in second-line RAS-mutant, MSS metastatic colorectal cancer at the European Society for Medical Oncology Congress 2026. The company said recent FDA interactions opened the option of a pivotal expansion (Part B) that could support an accelerated approval submission based on objective response rate and a full approval based on progression-free survival.
Key points
- The e-poster is presentation number 994eTiP, and the study will randomize 30 patients per arm.
- The primary endpoint is objective response rate; secondary endpoints include overall survival and progression-free survival.
- The filing says a possible Part B expansion could support accelerated approval based on ORR and full approval based on PFS, but no Part B has been initiated as stated in the filing.
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 20, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.